



Food and Drug Administration – Shortage of Vyvanse® (lisdexamfetamine) and generics

- Brand [Vyvanse \(lisdexamfetamine\)](#) and generics are in shortage due to increased demand and limited availability of active ingredient due to quotas set by the Drug Enforcement Agency (DEA) for controlled substances. Both [capsules](#) and [chewable tablets](#) are in short supply.
- Brand and generic Vyvanse are FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD) and binge-eating disorder.
- Amphetamine products are CII controlled substances. Production is controlled by the DEA and distribution quantities are closely monitored and regulated making it difficult to rapidly increase supply.
- The [FDA shortage site](#) provides updates on the shortage, including a list of current manufacturers and product strengths that are still available.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.